Biostar Pharmaceuticals (BSPM) 1.14 $BSPM
5 Under-$10 Stocks Setting Up to Trade Higher: Biostar Pharmaceuticals and More
at The Street - Fri Jan 16, 11:17AM CST
Looking for setups that often produce monster moves higher in very short time frames.
RADA: 2.46 (+0.01), BSPM: 1.14 (unch), SKH: 8.77 (+0.47), PPP: 3.35 (+0.06), CNET: 1.58 (+0.02)
Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with Northwest University for Further Development of Danshensu Yibingzhi (IDHP), a Class One Drug for Treatment of Cardiovascular Diseases
PR Newswire - Thu Jan 08, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on December 29, 2014, the Company signed a joint research and development agreement with Northwest University, one of China's leading comprehensive universities located in Xi'an city, Shaanxi Province, for further development of Danshensu Yibingzhi (IDHP), a Class One drug for treatment of cardiovascular diseases to further research and development efforts in connection with Danshensu Yibingzhi (IDHP).
BSPM: 1.14 (unch)
OTC Daily Alert Stock Watch - Biostar Pharmaceuticals, Inc., (NASDAQ: BSPM)
WorldStockWire - Mon Dec 29, 3:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
BSPM: 1.14 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:46AM CST
ZIOP: 9.64 (-0.35), BSPM: 1.14 (unch), BDR: 1.71 (-0.02), ZAZA: 2.17 (+0.08), ACY: 8.49 (+0.20), NBS: 3.78 (+0.14), SYRX: 1.50 (-0.06), IAG: 2.23 (-0.08), THTI: 1.01 (-0.09), BITA: 62.95 (+2.85), VRTB: 3.31 (-0.28), OPTT: 0.50 (-0.02), INVT: 0.59 (-0.02), GERN: 3.03 (unch), VASC: 26.44 (+0.79), LOCM: 0.65 (-0.03), CTHR: 1.63 (-0.01), MOV: 25.26 (-0.17), IFON: 1.48 (+0.02), SVM: 1.38 (+0.04)
Biostar Pharma revenues down in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:00AM CST
BSPM: 1.14 (unch)
Biostar Pharmaceuticals EPS of $0.02
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:08AM CST
BSPM: 1.14 (unch)
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Fri Nov 14, 8:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter ended September 30, 2014.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals, Inc. Files a PRC Patent Application for Oleanolic Acid Injection, its New Drug Product for Hepatitis B and Liver Cancer
PR Newswire - Thu Sep 18, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or the "Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today it has filed PRC national invention and creation patent for the pharmaceutical and preparation method of its new developed product, Oleanolic Acid Injection, which designed to treat Hepatitis B and liver cancer. The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals elects Professor Xiaohui Zheng as its chief scientist
M2 - Thu Aug 28, 7:11AM CDT
Pharmaceutical company Biostar Pharmaceuticals (NasdaqCM:BSPM) said on Wednesday that Professor Xiaohui Zheng has been named as its chief scientist to preside over its product development projects.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals Inc. Engaged Chief Scientist Professor Xiaohui Zheng To Preside Over The Company's Product Development Projects
PR Newswire - Wed Aug 27, 7:00AM CDT
XIANYANG, China, Aug. 27, 2014 /PRNewswire/-- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that the Company has hired Professor Xiaohui Zheng as its chief scientist to preside over the Company's product development projects.
BSPM: 1.14 (unch)
Nasdaq stocks posting largest volume increases
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PNTR: 7.90 (+0.01), BSPM: 1.14 (unch), LNDC: 14.30 (+0.20), HPJ: 5.71 (+0.16), HMPR: 1.64 (-0.02), IMCB: 20.00 (+0.31), BSQR: 4.53 (+0.05), DGLY: 11.50 (-0.40), MGYR: 8.45 (+0.04)
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
BSPM: 1.14 (unch), BAX: 70.39 (+0.31), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06), SNY: 49.42 (+0.82), CPHI: 0.34 (+0.03)
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 14, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the second quarter ended June 30, 2014.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals announces formation of hospital marketing team to open new sales channels in ten provinces in China
M2 - Tue Aug 05, 6:16AM CDT
Health supplement company Biostar Pharmaceuticals (NasdaqCM:BSPM) reported on Monday the establishment a dedicated sales and marketing team for developing and expanding the sales of its Huangyangning tablets, hyperthyroidism and Wenweishu capsules in ten provinces in China.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals Inc. Established a Sales and Marketing Task Team to Promote Sales to Hospital Facilities in Ten PRC Provinces
PR Newswire - Mon Aug 04, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it established a dedicated sales and marketing team for the purposes of developing and eventually expanding sales of the Company's Huangyangning tablets, hyperthyroidism and Wenweishu capsules to the top two tiered hospital facilities in ten PRC provinces, including, among others, in Beijing, Chongqing, Heilongjiang, Hebei and Henan provinces. To that end, in July 2014, the Company's opened a sales office in the high-tech development zone of Xi'an, the capital of Shaanxi province, which office, under the experienced management, will be primarily tasked with preparing sales and marketing team of as many as 200 sales representatives to target the top two tiered hospital facilities in the above-referenced PRC provinces.
BSPM: 1.14 (unch)
5 Under-$10 Stocks Setting Up to Trade Higher: Biostar Pharmaceuticals and More
at The Street - Fri Jan 16, 11:17AM CST
Looking for setups that often produce monster moves higher in very short time frames.
RADA: 2.46 (+0.01), BSPM: 1.14 (unch), SKH: 8.77 (+0.47), PPP: 3.35 (+0.06), CNET: 1.58 (+0.02)
Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with Northwest University for Further Development of Danshensu Yibingzhi (IDHP), a Class One Drug for Treatment of Cardiovascular Diseases
PR Newswire - Thu Jan 08, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on December 29, 2014, the Company signed a joint research and development agreement with Northwest University, one of China's leading comprehensive universities located in Xi'an city, Shaanxi Province, for further development of Danshensu Yibingzhi (IDHP), a Class One drug for treatment of cardiovascular diseases to further research and development efforts in connection with Danshensu Yibingzhi (IDHP). BSPM: 1.14 (unch)
OTC Daily Alert Stock Watch - Biostar Pharmaceuticals, Inc., (NASDAQ: BSPM)
WorldStockWire - Mon Dec 29, 3:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
BSPM: 1.14 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:46AM CST
ZIOP: 9.64 (-0.35), BSPM: 1.14 (unch), BDR: 1.71 (-0.02), ZAZA: 2.17 (+0.08), ACY: 8.49 (+0.20), NBS: 3.78 (+0.14), SYRX: 1.50 (-0.06), IAG: 2.23 (-0.08), THTI: 1.01 (-0.09), BITA: 62.95 (+2.85), VRTB: 3.31 (-0.28), OPTT: 0.50 (-0.02), INVT: 0.59 (-0.02), GERN: 3.03 (unch), VASC: 26.44 (+0.79), LOCM: 0.65 (-0.03), CTHR: 1.63 (-0.01), MOV: 25.26 (-0.17), IFON: 1.48 (+0.02), SVM: 1.38 (+0.04)
Biostar Pharma revenues down in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:00AM CST
BSPM: 1.14 (unch)
Biostar Pharmaceuticals EPS of $0.02
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:08AM CST
BSPM: 1.14 (unch)
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Fri Nov 14, 8:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter ended September 30, 2014. BSPM: 1.14 (unch)
Biostar Pharmaceuticals, Inc. Files a PRC Patent Application for Oleanolic Acid Injection, its New Drug Product for Hepatitis B and Liver Cancer
PR Newswire - Thu Sep 18, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or the "Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today it has filed PRC national invention and creation patent for the pharmaceutical and preparation method of its new developed product, Oleanolic Acid Injection, which designed to treat Hepatitis B and liver cancer. The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7. BSPM: 1.14 (unch)
Biostar Pharmaceuticals elects Professor Xiaohui Zheng as its chief scientist
M2 - Thu Aug 28, 7:11AM CDT
Pharmaceutical company Biostar Pharmaceuticals (NasdaqCM:BSPM) said on Wednesday that Professor Xiaohui Zheng has been named as its chief scientist to preside over its product development projects.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals Inc. Engaged Chief Scientist Professor Xiaohui Zheng To Preside Over The Company's Product Development Projects
PR Newswire - Wed Aug 27, 7:00AM CDT
XIANYANG, China, Aug. 27, 2014 /PRNewswire/-- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that the Company has hired Professor Xiaohui Zheng as its chief scientist to preside over the Company's product development projects. BSPM: 1.14 (unch)
Nasdaq stocks posting largest volume increases
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PNTR: 7.90 (+0.01), BSPM: 1.14 (unch), LNDC: 14.30 (+0.20), HPJ: 5.71 (+0.16), HMPR: 1.64 (-0.02), IMCB: 20.00 (+0.31), BSQR: 4.53 (+0.05), DGLY: 11.50 (-0.40), MGYR: 8.45 (+0.04)
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
BSPM: 1.14 (unch), BAX: 70.39 (+0.31), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06), SNY: 49.42 (+0.82), CPHI: 0.34 (+0.03)
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 14, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the second quarter ended June 30, 2014. BSPM: 1.14 (unch)
Biostar Pharmaceuticals announces formation of hospital marketing team to open new sales channels in ten provinces in China
M2 - Tue Aug 05, 6:16AM CDT
Health supplement company Biostar Pharmaceuticals (NasdaqCM:BSPM) reported on Monday the establishment a dedicated sales and marketing team for developing and expanding the sales of its Huangyangning tablets, hyperthyroidism and Wenweishu capsules in ten provinces in China.
BSPM: 1.14 (unch)
Biostar Pharmaceuticals Inc. Established a Sales and Marketing Task Team to Promote Sales to Hospital Facilities in Ten PRC Provinces
PR Newswire - Mon Aug 04, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it established a dedicated sales and marketing team for the purposes of developing and eventually expanding sales of the Company's Huangyangning tablets, hyperthyroidism and Wenweishu capsules to the top two tiered hospital facilities in ten PRC provinces, including, among others, in Beijing, Chongqing, Heilongjiang, Hebei and Henan provinces. To that end, in July 2014, the Company's opened a sales office in the high-tech development zone of Xi'an, the capital of Shaanxi province, which office, under the experienced management, will be primarily tasked with preparing sales and marketing team of as many as 200 sales representatives to target the top two tiered hospital facilities in the above-referenced PRC provinces. BSPM: 1.14 (unch)
